Name: GenWorks Health Private Limited | Best Medical device supplier
Address: Gamma Block, Sigma Soft Tech Park, Unit 522-524, 5th Floor, Bangalore, Karnataka, 560066, IN

Early Symptoms of Preeclampsia are often too Ambiguous for Accurate Clinical Stratification

Clinical presentations often involve uncertain indications of hypertension and proteinuria

Less than 40% of women exhibit both hypertension and proteinuria before the development of overt preeclampsia

Preeclampsia progression is unpredictable and often complicated by adverse outcomes

The Lumella® GlyFN Test is intended as an aid in the diagnosis of women with suspected Preeclampsia.

Normal GlyFN	50-250μg/mL	Correlated with normal pregnancy with high sensitivity of 98.2% and high Negative Predictive Value of 99.4%
Positive GlyFN	351-600 μg/mL	Correlated with biochemical diagnosis of preeclampsia with 98% Positive Predictive Value
High Positive GlyFN	>600 μg/mL	Correlated with risk of severe preclampsia with 99% Positive Predictive Value

I am interested in booking my lumella

Introducing the rapid point-of-care
test in early detection of preeclampsia

Early & Effective Screening can help save lives

Testing period: Gestational age 13-37 weeks

The Lumella test estimates the concentration of Glycosylated Fibronectin, a new pregnancy specific biomarker to accurately assess the risk of preeclampsia

Measures glycosylated fibronectin (GlyFN)

Uses 5 μL finger prick blood sample

Results in 10 minutes

Early Symptoms of Preeclampsia are often too Ambiguous for Accurate Clinical Stratification

Clinical presentations often involve uncertain indications of hypertension and proteinuria

Less than 40% of women exhibit both hypertension and proteinuria before the development of overt preeclampsia

Preeclampsia progression is unpredictable and often complicated by adverse outcomes

The Lumella® GlyFN Test is intended as an aid in the diagnosis of women with suspected Preeclampsia.

I am interested in booking my lumella

Introducing the rapid point-of-caretest in early detection of preeclampsia

Early & Effective Screening can help save lives

Testing period: Gestational age 13-37 weeks

The Lumella test estimates the concentration of Glycosylated Fibronectin, a new pregnancy specific biomarker to accurately assess the risk of preeclampsia

Measures glycosylated fibronectin (GlyFN)

Uses 5 μL finger prick blood sample

Results in 10 minutes

Early Symptoms of Preeclampsia are often too Ambiguous for Accurate Clinical Stratification

Clinical presentations often involve uncertain indications of hypertension and proteinuria

Less than 40% of women exhibit both hypertension and proteinuria before the development of overt preeclampsia

Preeclampsia progression is unpredictable and often complicated by adverse outcomes

The Lumella® GlyFN Test is intended as an aid in the diagnosis of women with suspected Preeclampsia.

Introducing the rapid point-of-care
test in early detection of preeclampsia